10 results on '"Loberiza, Fausto R."'
Search Results
2. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
- Author
-
Marks, David I., Oostrum, Ilse, Mueller, Sabrina, Welch, Verna, Vandendries, Erik, Loberiza, Fausto R., Böhme, Sarah, Su, Yun, Stelljes, Matthias, and Kantarjian, Hagop M.
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,HOSPITAL care ,CANCER chemotherapy ,TREATMENT duration - Abstract
Background: Inotuzumab Ozogamicin (INO), has demonstrated an improvement in overall survival, high rate of complete remission, favorable patient‐reported outcomes, and manageable safety profile vs standard of care (SoC; intensive chemotherapy) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase 3 INO‐VATE trial. With a one‐hour weekly dosing schedule, INO might be associated with lower healthcare system burden. This study analyses hospitalizations for INO vs SoC. Methods: All patients receiving study treatment in the INO‐VATE trial were included. The days hospitalized during study treatment was calculated. Due to different treatment durations for INO and SoC (median of 3 vs 1 cycles), number of hospital days was mainly reported per observed patient month. Hospital days per patient month were analyzed for different treatment cycles, subgroups, and main reasons for hospitalization. Differences between treatments were analyzed by the incidence rate ratio (IRR). Results: Overall, 82.9% and 94.4% INO and SoC patients experienced at least one hospitalization. The mean hospitalization days per patient month was 7.6 and 18.4 days for INO and SoC (IRR = 0.413, P < .001), which corresponds to patients spending 25.0% and 60.5% of their treatment time in a hospital. Main hospitalization reasons were R/R ALL treatment (5.2 (INO) vs 14.0 (SoC) days, IRR = 0.368, P < .001), treatment toxicities (1.4 vs 2.8 days, IRR = 0.516, P < .001) or other reasons (1.0 vs 1.6 days, IRR 0.629, P < .001). Conclusions: Inotuzumab Ozogamicin treatment in R/R ALL is associated with a lower hospitalization burden compared with SoC. It is likely this lower burden has a favorable impact on healthcare budgets and cost‐effectiveness considerations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Promoting oral cancer examinations to medical primary care providers: a cluster randomized trial.
- Author
-
Wee, Alvin G., Zimmerman, Lani M., Anderson, James R., Nunn, Martha E., Loberiza, Fausto R., Sitorius, Michael A., and Pullen, Carol H.
- Subjects
ORAL cancer diagnosis ,PRIMARY care ,CLUSTER randomized controlled trials ,ONLINE education ,HEALTH promotion ,MOUTH tumors ,COMPARATIVE studies ,EMPLOYEE orientation ,INTERNET ,RESEARCH methodology ,MEDICAL cooperation ,MENTAL health surveys ,PRIMARY health care ,RESEARCH ,EVALUATION research ,RANDOMIZED controlled trials ,DIAGNOSIS - Abstract
Objectives: To compare the percentage of patients who had an oral cancer examination (OCE) by their primary care provider (PCP) in medical clinics participating in a web-based education with poster reminder intervention to that of patients in control clinics. To also determine the effects for PCPs in medical clinics participating in the web-based education with poster reminder intervention as compared with those in control clinics regarding: a) index of knowledge of oral cancer risk factors (RiskOC) and b) index of knowledge of oral cancer diagnostic procedures (DiagOC).Methods: Six medical clinics were recruited to participate in this study and randomly assigned to an intervention group or a control group. PCPs (physicians, physician assistants, and advanced practice registered nurses) took a pretest; 2 weeks later, they participated in the web-based educational program, including a posttest (intervention group) or took a posttest only (control group). In each clinic, 1 week following completion of the PCPs' posttests, 94 patients were recruited to complete a one-page survey.Results: The intervention clinics were found to be a significant factor for the PCPs to perform patient OCEs, after controlling for significant covariates, that is, age, main reason for clinic visit, OCE for patient in the past year, clinic's mean DiagOC score, and clinic's mean RiskOC score. The intervention also resulted in the PCPs increasing their pretest to posttest RiskOC scores.Conclusions: The use of intervention has the potential to increase PCPs' short-term knowledge and to increase the frequency of PCPs' routine, nonsymptomatic opportunistic OCE on patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Late relapse in patients with diffuse large B-cell lymphoma J. M. Vose et al Late Relapse in DLBCL.
- Author
-
Vose, Julie M., Weisenburger, Dennis D., Loberiza, Fausto R., Arevalo, Alejandro, Bast, Martin, Armitage, Joel, Bierman, Philip J., Bociek, Robert G., and Armitage, James O.
- Subjects
DISEASE relapse ,LYMPHOMAS ,CYCLOPHOSPHAMIDE ,DOXORUBICIN ,VINCRISTINE - Abstract
The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P = 0·04), a normal lactic dehydrogenase (77% vs. 48%, P = 0·01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P = 0·01). The 3-year survival after relapse was better in late relapsing patients (48% vs. 25%, P = 0·03), but the survival at 5 years (32% vs. 20%) and 10 years (13% vs. 14%) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age ( P < 0·0001) and presence of B-symptoms ( P = 0·03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
5. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
- Author
-
Nelson, Marilu, Horsman, Douglas E., Weisenburger, Dennis D., Gascoyne, Randy D., Dave, Bhavana J., Loberiza, Fausto R., Ludkovski, Olga, Savage, Kerry J., Armitage, James O., and Sanger, Warren G.
- Subjects
CHROMOSOME abnormalities ,CYTOGENETICS ,LYMPHOMAS ,HODGKIN'S disease ,TRISOMY - Abstract
Cytogenetic correlations among most types of peripheral T-cell lymphoma (PTCL) have not been very informative to date. This study aimed to identify recurrent chromosomal abnormalities in angioimmunoblastic T-cell lymphoma (AITL), ALK-negative anaplastic large cell lymphoma ( ALK-ALCL) and peripheral T-cell lymphoma, unspecified (PTCL-US), and to evaluate their prognostic value. We reviewed the cytogenetic findings of 90 previously-diagnosed cases of PTCL and correlated the cytogenetic findings with the specific histological subtype. The most common abnormalities for AITL were 5q (55%), 21 (41%) and 3q (36%) gains, concurrent trisomies of 5 and 21 (41%), and loss of 6q (23%). In ALK(-) ALCL, gains of 1q (50%) and 3p (30%), and losses of 16pter (50%), 6q13q21 (30%), 15 (30%), 16qter (30%) and 17p13 (30%) were frequent findings. In PTCL-US, frequent gains involved 7q22q31 (33%), 1q (24%), 3p (20%), 5p (20%), and 8q24qter (22%), and losses of 6q22q24 (26%) and 10p13pter (26%). We did not observe any association between specific chromosomal abnormalities and overall survival (OS). However, cases with complex karyotypes, most frequently observed in ALK(-) ALCL and PTCL-US, had a significantly shorter OS. Although, genetic differences were noted in these subtypes, further studies are needed to determine the key pathogenetic events in PTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Health-related quality of life in children with sickle cell disease: child and parent perception.
- Author
-
Panepinto, Julie A., O'Mahar, Kerry M., DeBaun, Michael R., Loberiza, Fausto R., and Scott, J. P.
- Subjects
SICKLE cell anemia in children ,ANEMIA in children ,CHILDREN'S health ,QUALITY of life ,PEDIATRICS - Abstract
Health-related quality of life (HRQL) is an outcome that may be used to measure the impact of sickle cell disease on the child and their family but has not been routinely assessed in this disease. The objective of this study was to describe the HRQL of children with sickle cell disease as reported by the parent and the child, to compare the relationship between the two, and to determine the association of parent, child and disease characteristics on HRQL. Ninety-five parents completed the Child Health Questionnaire (CHQ)-Parent Form28 and 53 children completed the CHQ-Child Form87. Compared with the child report, parents reported worse HRQL in the overall perception of health, physical functioning, behaviour and self esteem domains of HRQL ( P < 0·005). Parent and child reports of HRQL correlated strongly in assessment of the impact of bodily pain ( r = 0·58) on HRQL and moderately in physical functioning ( r = 0·44), behaviour ( r = 0·45), general health ( r = 0·44), self esteem ( r = 0·40) and changes in health ( r = 0·33) domains. Disease status, neurobehavioral co-morbidities, and parent education were associated with the HRQL of the child. Both the parent and child perspectives are needed to fully understand the impact of sickle cell disease on the HRQL of the child and effect of this disease on the family. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses.
- Author
-
Ringdén, Olle, Barrett, A. John, Zhang, Mei-Jie, Loberiza, Fausto R., Bolwell, Brian J., Cairo, Mitchell S., Gale, Robert Peter, Hale, Gregory A., Litzow, Mark R., Martino, Rodrigo, Russell, James A., Tiberghien, Pierre, Urbano-Ispizua, Alvaro, and Horowitz, Mary M.
- Subjects
CD antigens ,HLA histocompatibility antigens ,STEM cells ,BONE marrow transplantation ,IMMUNE system - Abstract
Summary. We studied the association between CD34 cell dose and transplant outcomes in 359 bone marrow (BM) and 511 peripheral blood stem cell (PBSC) transplant recipients from human leucocyte antigen (HLA)-identical siblings, reported to the International Bone Marrow Transplant Registry (IBMTR). Transplants for leukaemia were performed between 1995 and 1998. Patients were divided into those receiving below or above the median CD34
+ dose, for BM (3 × 106 /kg) and PBSC (6 × 106 /kg) grafts respectively. Cox proportional hazards regression was used to adjust for baseline patient-, disease- and transplant-related characteristics. Analysis of the BM recipients showed that high CD34 cell dose was associated with lower transplant-related mortality [relative risk (RR) = 0·60, P = 0·033] and treatment failure (inverse of leukaemia-free survival, RR = 0·69, P = 0·032). Among PBSC recipients, high CD34 dose was associated with faster recovery of neutrophils to > 0·5 × 109 /l (RR = 1·38, P < 0·001) and platelets to > 20 × 109 /l (RR = 1·34, P = 0·003), lower risk of relapse (RR = 0·62, P = 0·029) and treatment failure (RR = 0·74, P = 0·03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
8. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
- Author
-
Vandenberghe, Elisabeth, Ruiz de Elvira, Carmen, Loberiza, Fausto R., Conde, E, López-Guillermo, A., Gisselbrecht, C., Guilhot, F., Vose, Julie M., Biesen, Koen van, Rizzo, J. Douglas, Weisenburger, Dennis D., Isaacson, Peter, Horowitz, Mary M., Goldstone, Anthony H., Lazarus, Hillard M., and Schmitz, Norbert
- Subjects
LYMPHOMAS ,AUTOTRANSPLANTATION - Abstract
Summary. Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multicentre study with adequate follow-up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow-up was analysed. One hundred and ninety-five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow-up of 3·9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2·99 times (95% CI: 1·66–5·38, P < 0·001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
9. Quality of Life Assessment in Nonmelanoma Cervicofacial Skin Cancer.
- Author
-
Rhee, John S., Loberiza, Fausto R., Matthews, B. Alex, Neuburg, Marcy, Smith, Timothy L., and Burzynski, Mary
- Abstract
Objectives/Hypothesis Health-related quality of life (QOL) assessment of patients with nonmelanoma skin cancer is poorly understood. The objectives of the study were to determine the general QOL of patients with cervicofacial skin cancer and to identify patient, clinical, and preventive behavior variables associated with patients' QOL. Study Design Cross-sectional study of 121 consecutive patients (65 female and 56 male patients) presenting to a dermatological Mohs surgery clinic with nonmelanoma skin cancer of the head and neck. Methods Quality of life assessment was performed before counseling or treatment. Measures included the Medical Outcomes Study Short Form 36-item Health Survey (SF-36) and the Functional Assessment of Cancer Therapy-General (FACT-G). Results Both instruments demonstrated good internal consistency as measured by Cronbach's alpha (SF-36, α = 0.45-0.91; FACT-G, α = 0.61-0.90). The SF-36 scores were similar to historical norms. Bivariate analysis indicated significant correlation coefficients between QOL and patients' coexisting illnesses and medical risk factors. Sun-protective behaviors were associated with better QOL. The relationship appeared to be minimally influenced by patients' sociodemographic characteristics and disease-related variables (size, location, extent). Conclusions Sun-protective behaviors were positively associated with certain QOL subscale scores in the population in the study. General QOL instruments demonstrated minimal impact of nonmelanoma skin cancer on patients at initial diagnosis. However, general measures may not be sensitive to the impact of nonmelanoma skin cancer. The development of a more disease-specific instrument may be necessary to evaluate this disease process. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
10. Sounding the alarm on deaths from suicide and accidents after hematopoietic stem cell transplantation.
- Author
-
Loberiza, Fausto R. and Cannon, Anthony J.
- Subjects
- *
HEMATOPOIETIC stem cells , *PATIENTS , *DISEASE risk factors - Abstract
An introduction is presented in which the editor discusses various articles within the issue on topics including risk factors associated with deaths from hematopoietic stem cell transplantation (HSCT), a case-control analysis on HSCT patients, and relapse of the HSCT.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.